Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saby George

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Current Oncology Reports|January 22, 2013
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancerSaby George, Roberto Pili
Clinical Advances in Hematology & Oncology : H&O|February 18, 2017
VEGF inhibitors in renal cell carcinomaPankit Vachhani, Saby George
Clinical Genitourinary Cancer|January 24, 2007
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapiesSaby George, Brian I Rini
Therapeutics and Clinical Risk Management|September 24, 2009
Role of everolimus in the treatment of renal cell carcinomaSaby George, Ronald M Bukowski
World Neurosurgery|September 3, 2016
Pituitary Apoplexy After Initial Leuprolide InjectionAndrew J Fabiano, Saby George
Expert Review of Anticancer Therapy|December 8, 2007
Biomarkers in clear cell renal cell carcinomaSaby George, Ronald M Bukowski
Immunotherapy|March 2, 2023
Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancerArya Mariam Roy, Saby George
Cancer Drug Resistance (Alhambra, Calif.)|October 16, 2023
Emerging resistance <i>vs.</i> losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomenaArya Mariam Roy, Saby George
Urologic Oncology|September 10, 2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A reviewRohit K Jain, Shipra Gandhi, Saby George
JAMA Oncology|November 27, 2018
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A ReviewSaby George, Brian I Rini, Hans J Hammers
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Current Oncology Reports|January 22, 2013
Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancerSaby George, Roberto Pili
Clinical Advances in Hematology & Oncology : H&O|February 18, 2017
VEGF inhibitors in renal cell carcinomaPankit Vachhani, Saby George
Clinical Genitourinary Cancer|January 24, 2007
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapiesSaby George, Brian I Rini
Therapeutics and Clinical Risk Management|September 24, 2009
Role of everolimus in the treatment of renal cell carcinomaSaby George, Ronald M Bukowski
World Neurosurgery|September 3, 2016
Pituitary Apoplexy After Initial Leuprolide InjectionAndrew J Fabiano, Saby George
Expert Review of Anticancer Therapy|December 8, 2007
Biomarkers in clear cell renal cell carcinomaSaby George, Ronald M Bukowski
Immunotherapy|March 2, 2023
Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancerArya Mariam Roy, Saby George
Cancer Drug Resistance (Alhambra, Calif.)|October 16, 2023
Emerging resistance <i>vs.</i> losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomenaArya Mariam Roy, Saby George
Urologic Oncology|September 10, 2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A reviewRohit K Jain, Shipra Gandhi, Saby George
JAMA Oncology|November 27, 2018
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A ReviewSaby George, Brian I Rini, Hans J Hammers
Pageof 10